ArticleJournal of thoracic disease2016

A potential new therapeutic option for patients with advanced EGFR mutation-positive non-small cell lung cancer in first-line setting.

Cesare Gridelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.